Ascentage hopes to become a new force in BTK.
ApexOnco Front Page
Recent articles
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
The company impresses investors, but money’s running short.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
